title: [Betatrophin - the turn in diabetes treatment].
abstract: The topic of the present work is the appearance of the newest research in diabetes treatment. Till now, the patients were forced to inject insulin or take oral medicines to maintain proper glucose level. Introduction of the incretin group of medicines to the market turned out to be a breakthrough in diabetes treatment. It defers the necessity of insulin therapy in type 2 diabetes. Studies connected with amyline were the next step in diabetes therapy. The new research connected with peptide betatrophin seems to comes as the biggest surprise and hope for diabetics. The hormone stimulates B-cells proliferation, which leads to increase in endogenous insulin production. It generates a chance for a fewer number of injections, which will result in better quality of life.
authors.forename: Zygmunt
authors.initials: Z
authors.lastname: Zdrojewicz
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Otlewska
authors.forename: Anna
authors.initials: A
authors.lastname: Otlewska
authors.forename: Grzegorz
authors.initials: G
authors.lastname: Szpotowicz
authors.forename: Dorota
authors.initials: D
authors.lastname: Wasińska
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001402:B-Lymphocytes / Q000187:drug effects*; D049109:Cell Proliferation / Q000187:drug effects*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000096:biosynthesis*; D008297:Male; D008875:Middle Aged; D036361:Peptide Hormones / Q000627:therapeutic use*
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin; D036361:Peptide Hormones